Information  X 
Enter a valid email address

Synairgen losses deepen on higher R&D spend

By BFN News | 01:07 PM | Tuesday 25 September, 2018

Respiratory drug company Synairgen posted a deeper first-half loss as it ramped up spending trialling a treatment for chronic obstructive pulmonary disease. Pre-tax losses for the six months through June amounted to £1.85m, widening from a loss of £1.57m on-year. Cash and bank deposits at 30 June were worth £5.31m. 'Synairgen has made good progress in the first half of 2018,' chief executive Richard Marsden said. 'We are pleased to see that the Phase II clinical trial assessing interferon beta in COPD has started well and we look forward to continuing with the second part of the trial later this year.' 'Our efforts will also focus on a number of potentially interesting collaborative opportunities to further strengthen our pipeline of therapies.' At 1:07pm: (LON:SNG) Synairgen PLC share price was -0.95p at 17p Story provided by

a d v e r t i s e m e n t